Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
 
Working Life
Welcome to the world of the medical director
The role of medical director is vital to the success of any pharmaco but it requires both medical expertise and, increasingly, a commercial focus, writes Karen Keast.
Pipeline Monitor
New US approvals in MS and insomnia
A first in class insomnia drug, a fortnightly injection for MS and a potential biosimilar competitor for Sanofi's Lantus have won approval from the FDA.
Approvals Action
Competitors for vertigo treatment
Meniere's disease treatment betahistine, originally registered by Abbott as Serc, has a slew of new competing brands thanks to Generic Partners.
Special Report
Pharma's future: old questions, new surprises
The pulse of pharma may be strong but there's no harm in an occasional health check and this one found plenty of differing views about where industry is headed over the coming decades.
Open Forum
Crestor appeal restores legal status quo
One aspect of the Full Federal Court's decision on the Crestor appeal restored an important status quo in legal terms although it didn't change the market reality writes Clare Young of law firm Allens Linklaters.
Working Life
Pfizer folks in 'give back' program
Pfizer employees talk about how they have been able to 'give back' by helping to develop more efficient health services for communities in need around the world.
Pipeline Monitor
New uses for Enbrel, Avastin, Eylea
European authorities have granted new indications to Pfizer's Enbrel, Roche's Avastin and Bayer's Eylea that are yet to come to Australia.